

CITATION REPORT

List of articles citing

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

DOI: 10.1056/nejmoa2022926

New England Journal of Medicine, 2020, 383, 2030-2040.

Source: <https://exaly.com/paper-pdf/75496536/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
883	Do cross-reactive antibodies cause neuropathology in COVID-19?. 2020 , 20, 645-646		33
882	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. 2020 , 80, 1929-1946		45
881	Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes. 2020 ,		13
880	[SARS-COV-2 myocarditis. An update]. 2020 , 69, 349-354		1
879	Novel coronavirus disease in patients with end-stage kidney disease. 2021 , 25, 544-550		4
878	Finding the right time for anti-inflammatory therapy in COVID-19. 2020 , 101, 247-248		5
877	The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. 2020 , 72, 1529-1537		6
876	Early adoption of critical care interventions is unjustifiable without concomitant effectiveness study. 2020 , 24, 649		0
875	The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'. 2020 , 41, 4389-4390		3
874	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. 2020 , 1, 100146		13
873	Hydroxychloroquine for COVID-19: Balancing contrasting claims. 2020 , 82, 25-26		4
872	COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis. 2020 , 14, 5097-5108		4
871	Knowing more about chloroquine/hydroxychloroquine in COVID-19 patients. 2020 , 15, 1523-1526		3
870	Recommendations for treatment of critically ill patients with COVID-19 : Version 3 S1 guideline. 2020 , 1		11
869	Lung transplantation for patients with severe COVID-19. 2020 , 12,		94
868	Prone positioning and convalescent plasma therapy in a critically ill pregnant woman with COVID-19. 2020 , 8, 3352-3358		4
867	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. 2020 , 8,		4

866	Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. 2020 , 6,	117
865	Drug treatments for covid-19: living systematic review and network meta-analysis. 2020 , 370, m2980	331
864	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. 2020 , 2, e735-e736	3
863	COVID-19 update: The race to therapeutic development. 2020 , 53, 100733	33
862	Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. 2020 , 7, ofaa319	8
861	Bacterial and fungal superinfections in critically ill patients with COVID-19. 2020 , 46, 2071-2074	50
860	Haemoperfusion should only be used for COVID-19 in the context of randomized trials. 2020 , 16, 697-699	5
859	Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. 2020 , 9,	8
858	Rationale for COVID-19 Treatment by Nebulized Interferon-β-Literature Review and Personal Preliminary Experience. 2020 , 11, 592543	5
857	Update on COVID-19 Myocarditis. 2020 , 56,	18
856	[Lung changes in COVID-19-Pulmonary surfactant deficiency? : Perhaps not a far-fetched hypothesis]. 2020 , 115, 152-153	
855	Current Trends in Analytical Methods for the Determination of Hydroxychloroquine and Its Application as Treatment for COVID-19. 2020 , 5, 14602-14612	4
854	Is it prime time to consider a clinical trial of doxycycline for the management of COVID-19?. 2020 ,	2
853	Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. 2020 , 9, 1247-1254	6
852	Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19. 2020 , 10,	5
851	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. 2020 , 324, 2165-2176	206
850	[Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital]. 2020 ,	3
849	Severe Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2451-2460	59.2 613

848	Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 1757-1766	59.2	627
847	Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation. 2021 , 128, 104102		16
846	The influence of the learning health system to address the COVID-19 pandemic: An examination of early literature. 2021 , 36, 244-251		0
845	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. 2021 , 3, e19-e27		28
844	Low-Dose Dexamethasone Following IVIG in Pediatric Inflammatory Multisystem Syndrome in Temporal Association with COVID-19 (PIMS-TC). 2021 , 88, 301-302		2
843	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. 2021 , 72, e835-e843		59
842	The Urgency of Justice in Research: Beyond COVID-19. 2021 , 27, 97-100		11
841	Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. <i>New England Journal of Medicine</i> , 2021 , 384, 497-511	59.2	1158
840	The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment?. 2021 , 103, 1-2		8
839	Hydroxychloroquine with or without Azithromycin in Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 190	59.2	
838	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. 2021 , 14, 95-103		30
837	Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. 2021 , 57, 106247		4
836	Evaluation of potential anti-COVID-19 therapies. 2021 , 3, FDD54		0
835	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. 2021 , 41, 1375-1426		11
834	Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response. 2021 , 27, 920-921		11
833	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488		14
832	Management of Arrhythmias Associated with COVID-19. 2020 , 23, 2		27
831	The place for remdesivir in COVID-19 treatment. 2021 , 21, 20-21		52

830	Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data. 2020 , 148, 2407		4
829	Favipiravir and the Need for Early Ambulatory Treatment of COVID-19. 2021 , 65,		0
828	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102		7
827	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. 2021 , 232, 13-36		26
826	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of , , and clinical trials. 2021 , 11, 1207-1231		17
825	[Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic]. 2021 , 31, 243-244		
824	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 905-914	59.2	203
823	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. 2021 , 893, 173813		14
822	A snapshot of COVID-19 infection in patients with solid tumors. 2020 , 148, 2389		4
821	Anaesthesia research capacity: time for a rethink in light of the COVID-19 pandemic. 2021 , 76, 574-575		1
820	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 229-237	59.2	717
819	Has the door closed on hydroxychloroquine for SARS-COV-2?. 2021 , 27, 3-5		3
818	DGI recommendations for COVID-19 pharmacotherapy. 2021 , 49, 369-370		1
817	Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. 2021 , 49, 539-542		24
816	"Kit-covid" and the Popular Pharmacy Program in Brazil. 2021 , 37, e00348020		0
815	COVID-19 2020: The Experience of a London Teaching Hospital's Nephrology Service. 2021 , 46, 137-141		1
814	The strange case of hydroxychloroquine and COVID-19. 2021 ,		1
813	COVID19 pandemic is a «pandemic» of antimicrobial therapy. 2021 , 23, 5-15		2

812	Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. 2021 , 16, 843-852	18
811	Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19). 2021 , 35, e14221	6
810	Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IBV-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry.	2
809	Reply to Richier et al. 2021 ,	1
808	Suboptimal personal protective equipment and SARS-CoV-2 infection in Nephrologists: a Spanish national survey. 2021 , 14, 1216-1221	3
807	[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19]. 2021 , 75, 88-112	14
806	Japanese Rapid/Living recommendations on drug management for COVID-19. 2021 , 8, e664	6
805	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. 2021 , 25, 441-452	2
804	Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries. 2021 , 49, 543-575	11
803	COVID-19 Pandemisinde Kullanılan İlaçlar, Etki Mekanizmaları ve Etkililikleri. 00,	0
802	Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial.	14
801	Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial.	4
800	Misinformation about COVID-19: evidence for differential latent profiles and a strong association with trust in science. 2021 , 21, 89	58
799	Mask mandates in light of DANMASK-19. 2021 , 1-2	
798	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. 2021 , 131,	3
797	BJS commission on surgery and perioperative care post-COVID-19. 2021 , 108, 1162-1180	3
796	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. 2021 , 36, e83	10
795	The Twin Crises of Covid-19 and Racism: Pragmatic Mastery, Theory, Religion, and Ethics. 2021 , 7, 69-82	

794	Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. 2021 , 105, 1333-1343	29
793	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. 2021 , 49, e219-e234	119
792	High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. 2021 , 16, e0243964	16
791	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. 2021 , 10, 2126-2139	1
790	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. 2021 , 71, 411-432	1
789	Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19. 2021 , 16, e0245296	16
788	Actualizaci3n del manejo cl3nico de COVID-19 en pediatria: a un a3o de pandemia. 2021 , 88, 31-45	2
787	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. 2021 , 28,	11
786	Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients. 2021 , 116, 692-699	14
785	[Chronic inflammatory bowel diseases: what happens when SARS-CoV-2 occurs? Preliminary results from a study conducted at the Hassan II University Teaching Hospital in Fes, Morocco (a case report)]. 2021 , 38, 382	
784	[COVID-19 and renal transplantation]. 2021 , 16, 1-8	0
783	Five Critical Genes Related to Seven COVID-19 Subtypes: A Data Science Discovery. 2021 , 142-150	3
782	Estado actual de los tratamientos para la COVID-19. 2021 , 28, 40-56	2
781	Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality. 2021 , 57, 106254	2
780	Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages. 2021 , 12, 2042098621998876	
779	Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. 2021 , 5, rkab014	3
778	A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report. 2021 , 28, 248-253	10
777	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,	28

776	Ventilator-associated pneumonia in critically ill patients with COVID-19. 2021 , 25, 25	87
775	Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?. 2020 , 11, 571416	126
774	Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial.	2
773	Immune cartography of macrophage activation syndrome in the COVID-19 era. 2021 , 17, 145-157	30
772	Coronavirus disease 2019 management. 2021 , 27, 169-175	1
771	Azithromycin, RECOVERY, and the power of large, simple trials. 2021 , 397, 559-560	2
770	Methodological quality of COVID-19 clinical research. 2021 , 12, 943	30
769	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. 2021 ,	21
768	Reports of three long-term lung disease following SARS-CoV-2 infection. 2021 , 93, 2585-2587	
767	Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities. 2021 , 21, 42	4
766	Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19. 2021 , 41, 221-233	23
765	COVID-19 and the generation of novel scientific knowledge: Research questions and study designs. 2021 , 27, 694-707	1
764	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial.	65
763	2021 Acute Respiratory Distress Syndrome Update, With Coronavirus Disease 2019 Focus. 2021 ,	7
762	Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. 2021 , 73, 962-965	7
761	Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians. 2021 , 42, 882-883	2
760	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. 2021 , 35, e21409	27
759	Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. 2021 , 13,	11

758	Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. <i>New England Journal of Medicine</i> , 2021 , 384, 610-618	59.2	44 ^o
757	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. 2021 , 10, 1945		2
756	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. 2021 , 8, 604087		
755	Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis. 2021 , 65, 702-710		8
754	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. 2021 ,		19
753	Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. 2021 , 43, 23-32		16
752	Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study. 2021 , 61, 28-39		
751	[Hemophagocytic lymphohistiocytosis in critically ill patients]. 2021 , 116, 129-134		2
750	A matched cohort study of convalescent plasma therapy for COVID-19. 2021 , 36, 523-532		9
749	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. 2021 , 54, 37-45		2
748	Akt-independent effects of tricitiribine on ACE2 expression in human lung epithelial cells: Potential benefits in restricting SARS-CoV2 infection. 2021 , 236, 6597-6606		3
747	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. 2021 , 12, 631139		43
746	Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. 2021 , 76, 537-548		54
745	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. 2021 , 22,		5
744	Corticosteroids in COVID-19: A double-edged sword - a retrospective study. 2021 ,		o
743	Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease. 2021 , 12, 636989		17
742	Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. 2021 , 115, 139-150		10
741	Unresolved questions about the treatment of COVID-19 with corticosteroids. 2021 , 156, 143-144		o

740	The Immunopathology of COVID-19 and the Cannabis Paradigm. 2021 , 12, 631233	9
739	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 , 397, 605-612	117
738	Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis. 2021 , 32, 100743	8
737	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. 2021 , 8, 606755	2
736	Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection. 2021 , 13,	4
735	The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. 2021 , 73, 1473-1479	17
734	The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication.	3
733	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. 2021 , 61, 429-460	13
732	Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 1015-1027	59.2 251
731	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. 2021 , 4, 613-623	3
730	Chloroquine and COVID-19: role as a bitter taste receptor agonist?. 2021 , 40, 100843	
729	A Retrospective Analysis of the Impact of the Coronavirus Disease 2019 Pandemic on Health Care Workers in a Tertiary Hospital in Turkey. 2021 , 47, 948-954	
728	Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. 2021 , 14,	4
727	Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. 2021 , 16, e0248009	28
726	French Public Familiarity and Attitudes toward Clinical Research during the COVID-19 Pandemic. 2021 , 18,	2
725	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. 2021 , 6, 71	1
724	Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. 2021 , 325, 1185-1195	110
723	Acridavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses.	1

722	Wie häufig sind unkomplizierte Infektionen in der ambulanten Rheumaversorgung? Ergebnisse einer Befragung von Patienten mit rheumatischen Erkrankungen.		
721	COVID-19 in Brazil: A Message to the World. 2021 , 43, 238-239		1
720	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. 2021 , 104, 7-14		9
719	Real-life use of remdesivir in hospitalized patients with COVID-19. 2021 , 34, 136-140		6
718	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. 2021 , 19, e3001128		25
717	Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19. 2021 , 160, 1012-1013		3
716	COVID-19 in early 2021: current status and looking forward. 2021 , 6, 114		74
715	Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis. 2021 , 21, 247		11
714	Una presentación infrecuente de COVID-19, con diarrea como síntoma inicial, el primer caso diagnosticado en Cartagena, Colombia.. 2021 , 10, 65-74		
713	Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 881-882	59.2	4
712	Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. 2021 , 10,		3
711	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. 2021 , 22, 1257-1266		4
710	Coronavirus disease 2019 (COVID-19) and QTc prolongation. 2021 , 21, 158		8
709	How to Treat COVID-19 Patients at Home in the Italian Context: An Expert Opinion. 2021 , 13, 251-258		4
708	COVID-19 in Children: Respiratory Involvement and Some Differences With the Adults. 2021 , 9, 622240		4
707	Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19. 2021 , 25, 101549		5
706	Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. 2021 , 9,		7
705	Drug repurposing for COVID-19 via knowledge graph completion. 2021 , 115, 103696		28

704	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. 2021 , 57,	76
703	Nowcasting epidemics of novel pathogens: lessons from COVID-19. 2021 , 27, 388-395	11
702	What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. 2021 , 13, 175-184	5
701	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. 2021 , 246, 1533-1540	1
700	Precision therapeutic targets for COVID-19. 2021 , 18, 66	15
699	COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. 2021 , 254, 307-331	29
698	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. 2021 , 12, 632677	28
697	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. 2021 , 13, 259-284	12
696	The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. 2021 , 100, e25532	
695	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. 2021 , 9, 436-446	3
694	Neutralizing monoclonal antibodies for treatment of COVID-19. 2021 , 21, 382-393	227
693	Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. 2021 , 12, 631869	1
692	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. 2021 , 17, 371-387	31
691	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. 2021 , 11, 9023	21
690	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. 2021 , 22,	10
689	Paediatric research in the times of COVID-19. 2021 , 90, 267-271	2
688	Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis. 2021 , 9, 524	
687	The Reply. 2021 , 134, e300	

686	The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. 2021 , 897190021997399	1
685	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. 2021 , 12, 576093	10
684	COVID-19: Antiviral Tedavi.	
683	Cardiovascular protective properties of oxytocin against COVID-19. 2021 , 270, 119130	12
682	A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR).	9
681	Timing and dosage may be the key in the realisation of hydroxychloroquine+ azithromycin treatment benefit in Covid-19 elderly patients. 2021 , 57, 106314	2
680	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. 2021 , 23, 28	7
679	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. 2021 , 41, 1189-1202	5
678	Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity. 2021 , 4, 2100087	3
677	Two Key Takeaways From a Year of Pandemic Research. 2021 , 49, 1223-1226	1
676	Outcomes of non-COVID-19 critically ill patients during the COVID-19 pandemic : A retrospective propensity score-matched analysis. 2021 , 133, 942-950	2
675	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. 2021 , 13,	12
674	Mid-Regional pro-Adrenomedullin (MR-proADM), C-Reactive Protein (CRP) and Other Biomarkers in the Early Identification of Disease Progression in COVID-19 Patients in the Acute NHS Setting.	
673	Current COVID-19 treatments: Rapid review of the literature. 2021 , 11, 10003	13
672	High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?. 2021 , 16, 1329-1330	4
671	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. 2021 , 9, E693-E702	7
670	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. 2021 , 12, 2349	83
669	The time to offer treatments for COVID-19. 2021 , 30, 505-518	9

668	COVID-19 pneumonia successfully managed with high-flow nasal cannula in a 15-year-old boy. 2021 , 14,	
667	Influenza and COVID-19: Times Don't Get No Better. 2021 , 18, 586-587	
666	Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. 2021 , 16, e0249036	1
665	Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). 2021 , 42, 5-18	1
664	Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?. 2021 , 897, 173928	8
663	How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols. 2021 , 8, ofab072	4
662	Moments in autophagy and disease: Past and present. 2021 , 82, 100966	7
661	Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. 2021 , 21, 2573-2582	19
660	Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. 2021 , 16, e0251754	7
659	COVID-19-Associated Pneumonia: Radiobiological Insights. 2021 , 12, 640040	3
658	Are countries' precautionary actions against COVID-19 effective? An assessment study of 175 countries worldwide. 2021 , 29, 391-409	2
657	Determination of the outcomes of pathogenetic therapy in patients with SARS-CoV-2-associated pneumonia. 2021 , 40, 27-33	1
656	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. 2021 , 8, 681-691	2
655	Hydroxychloroquine as prophylaxis when treating patients with coronavirus disease 2019 □ Perception of frontline health care workers in South India. 73, 141-146	
654	The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review. 2021 , 151, 1854-1878	24
653	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- α and hydroxychloroquine in hospitalized patients with COVID-19. 2021 , 27, 1826-1837	27
652	Mortality trends among hospitalised COVID-19 patients in Sweden: A nationwide observational cohort study. 2021 , 4, 100054	17
651	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. 2021 , 12, 675419	13

650	Factors influencing risk perception and nosocomial infection prevention practices of frontline nurses during the COVID-19 pandemic. 2021 , 20, 78	3
649	Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?. 2021 , 39, 430-445	1
648	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	11
647	Measuring the QT interval on the go. 2021 , 28, 358-359	
646	Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations. 2021 , 22, 370	0
645	COVID-19 is not "just another flu": a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria. 2021 , 49, 907-916	1
644	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 , 397, 1637-1645	537
643	A Retrospective Study of COVID-19-Related Urgent Medical Visits and Hospitalizations After Outpatient COVID-19 Diagnosis in the US. 2021 , 38, 3185-3202	2
642	Reassessing the Association of Vitamin D Level With SARS-CoV-2 Seropositivity. 2021 , 4, e2111750	1
641	How COVID-19 has fundamentally changed clinical research in global health. 2021 , 9, e711-e720	20
640	COVID-19 combined with liver injury: Current challenges and management. 2021 , 9, 3487-3497	0
639	Pitfalls and perils of survival analysis under incorrect assumptions: the case of COVID-19 data. 2021 , 41, 21-28	1
638	Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PROACT-COVID study in The Netherlands. 2021 , 9, 813	1
637	Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium. 2021 , 3, e0438	8
636	The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. 2021 , 9,	3
635	Antiviral treatment selection for SARS-CoV-2 pneumonia. 2021 , 15, 985-992	1
634	What we know and dont know on SARS-CoV-2 and COVID-19. 2021 , 21, e8198	
633	A Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and. 2021 , 13,	3

632	Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppression. 2021 , 35, e14297	4
631	Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. 2021 , 11, 10599	9
630	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. 2021 , 238, 569-578	0
629	Case Report: Development of Miliary Pulmonary Tuberculosis in a Patient with Peritoneal Tuberculosis after COVID-19 Upper Respiratory Tract Infection. 2021 ,	2
628	Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis. 2021 , 16, e0251262	1
627	Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic. 2021 , 4, e2110775	5
626	When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?. 2021 ,	1
625	Efficacy of a Polyphenolic, Standardized Green Tea Extract for the Treatment of COVID-19 Syndrome: A Proof-of-Principle Study. 2021 , 1, 2-12	7
624	A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. 2021 , 106, 265-268	0
623	AIDS and COVID: A tale of two pandemics and the role of statisticians. 2021 , 40, 2499-2510	7
622	Clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak of the pandemic. 2021 , 106, 43-51	5
621	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. 2021 , 84, 1254-1268	42
620	The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19. 2021 , 12, 584940	7
619	Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. 2021 , 11, 73	7
618	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. 2021 , 151, 112106	3
617	Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry. 2021 , 10,	7
616	Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19. 2021 , 46, 1308-1311	1
615	Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. 2021 , 373, n1038	19

614	Hydroxychloroquine For Prophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial..	5
613	Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. 2021 , 19, 68	2
612	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. 2021 , 10,	5
611	Coronavirus Disease 2019 and Kidney Transplantation in Saudi Arabia: Outcomes and Future Opportunities. 2021 , 26, e931832	4
610	Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19.	1
609	Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. 2021 , 14, 715-734	1
608	COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation. 2021 , 16, e0253465	1
607	Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis. 2021 , 88, 63-72	4
606	Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis. 2021 , 25, 515-522	1
605	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	5
604	The role of antirheumatics in patients with COVID-19. 2021 , 3, e447-e459	19
603	Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis. 2021 , 11, 13588	4
602	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. 2021 , 115, 456-466	5
601	Clinical Management of COVID-19 Patients - An Update. 2022 , 52, 4-10	7
600	Future developments in the prevention, diagnosis and treatment of COVID-19. 2021 , 73, 56-80	2
599	COVID-19 chemoprevention. 2021 , 107, 31-33	
598	Use of hiPSC-derived cardiomyocytes to rule out proarrhythmic effects of drugs: the case of hydroxychloroquine in COVID-19.	
597	Clinical trials during pandemics and beyond: time for a more efficient pharmacological strategy. 2021 , 76, 2234-2236	1

596	Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. 2021 , 224, S1-S21	12
595	Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19. 2021 , 8, 648005	12
594	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	37
593	COVID-19 in heart transplant recipients during February-August 2020: A systematic review. 2021 , 35, e14390	2
592	COVID-19: Sleep, Circadian Rhythms and Immunity - Repurposing Drugs and Chronotherapeutics for SARS-CoV-2. 2021 , 15, 674204	5
591	Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. 2021 , 120 Suppl 1, S77-S85	3
590	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. 2021 , 3, 1257-1272	3
589	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. 2021 , 11,	23
588	Australia needs a prioritised national research strategy for clinical trials in a pandemic: lessons learned from COVID-19. 2021 , 215, 56-58.e1	1
587	Hydroxychloroquine Use Is Not Associated With QTc Length in a Large Cohort of SLE and RA Patients. 2021 ,	1
586	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. 2021 , 6, 100123	5
585	Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?. 2021 , 8, ofab318	3
584	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. 2021 , 1	15
583	Why electronic health records can do something big for clinical research. 2021 , 144, 1615-1616	0
582	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. 2021 ,	11
581	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. 2021 , 558, 1-12	9
580	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. 2021 , 120 Suppl 1, S6-S18	4
579	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. 2021 , 17,	0

578	Efficacy and Safety of Hydroxychloroquine for Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis. 2021 , 10,	3
577	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. 2021 , 2021, 5556207	2
576	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. 2021 , 10,	2
575	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. 2021 , 10,	2
574	[SARS-CoV-2 infection: Available data on 15th April 2021]. 2021 , 38, 616-625	
573	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. 2021 , 150, 190-202	14
572	COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. 2021 , 232, 1-12	22
571	Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. 2021 , 190, 2405-2419	4
570	Heterozygous gain-of-function variants cause an autoinflammatory immunodeficiency. 2021 , 6,	6
569	Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy. 2021 , 25, 435-449	8
568	Friends or Foes? An Update on Retinal Toxicities of Systemic Medications. 2021 , 52, 302-306	
567	Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. 2021 , 16, e0252388	2
566	An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan. 2021 , 10,	11
565	Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City. 2021 , 12, 668678	2
564	Therapeutic approaches to tackle COVID-19: An overview. 2021 , 8, 121-135	
563	What we have learned from COVID-19 pandemic?. 2021 , 120 Suppl 1, S1-S5	0
562	Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia. 2021 , 15, 1181-1187	
561	Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. 2021 , 27, 882-889	10

560	SARS-CoV-2 Antiviral Therapy. 2021 , e0010921	12
559	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. 2021 , 14, 3419-3428	4
558	Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. 2021 , 11,	4
557	What do we do with our under-enrolled single-center COVID-19 clinical trials?. 2021 , 18, 741-742	0
556	Differences in Inflammatory Marker Kinetics between the First and Second Wave of COVID-19 Patients Admitted to the ICU: A Retrospective, Single-Center Study. 2021 , 10,	4
555	Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection. 2021 , 77, S305-S311	2
554	The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19. 2021 , 117, e110-e113	1
553	Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large State-wide Health System During the Pandemic in 2020.	0
552	The Value of Medical Registries and Observational Studies Early in Pandemics: The COVID-19 Experience. 2021 ,	2
551	Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. 2021 , 96, 107636	6
550	COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection. 2021 , 2,	
549	Influence of statin treatment in a cohort of patients admitted for COVID-19. 2021 ,	2
548	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? - The Summarising Review. 2021 , 66, 1603975	0
547	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. 2021 , 47, 867-886	20
546	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. 2021 , 108, 370-376	3
545	Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis. 2021 , e2276	2
544	Opportunities for the use of routinely collected data for the generation of large randomized evidence in Colombia. 6, 182	
543	Tocilizumab and SARS-CoV-2 (COVID-19): An Evolving Story, the Picture Is Clearer. 2021 , 29, e199-e201	

542	Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. 2021 , 14,	3
541	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2021 , 10, 1837-1885	10
540	Distinctive features of severe SARS-CoV-2 pneumonia. 2021 , 131,	16
539	Clinical presentation, outcomes and factors associated with mortality: A prospective study from three COVID-19 referral care centres in West Africa. 2021 , 108, 45-52	3
538	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. 2021 , 2021, 1-22	0
537	Treatment of COVID-19 in Patients With Sarcoidosis. 2021 , 8, 689539	1
536	Concerning Pathophysiology and Justifying Clinical Trials. 2021 , 134, e439	0
535	Contemporary narrative review of treatment options for COVID-19. 2021 , 26, 745-767	6
534	Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian Patients: Preliminary Report of a Data Mining Study. 2021 , 2021, 9934134	0
533	Roles of steroid receptors in the lung and COVID-19. 2021 , 65, 1025-1038	2
532	The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. 2021 , 121, 705-714	3
531	What can a learning healthcare system teach us about improving outcomes?. 2021 , 27, 527-536	1
530	Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates. 2021 ,	7
529	[Potentially useful drugs in the treatment of COVID-19 in Primary Care]. 2021 ,	
528	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. 2021 , 138, 1768-1773	12
527	Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.	1
526	Epidemiology and Clinical Characteristics in Individuals with Confirmed SARS-CoV-2 Infection During the Early COVID-19 Pandemic in Saudi Arabia.	
525	Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. 2021 , 18, e1003682	29

524	Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. 2021 ,	3
523	Outpatient Management of COVID-19 Disease: A Holistic Patient-Centered Proposal Based on the Greek Experience. 2021 , 11,	1
522	Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. 2021 , 54, 787-793	8
521	Making trials part of good clinical care: lessons from the RECOVERY trial. 2021 , 8, e243-e250	6
520	Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry. 2021 , 11, 15097	2
519	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through IB of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. 2021 , 1, 263-275	0
518	India and management of COVID-19: A case study on published guidelines. 2021 , 15, 171-179	
517	Health emergencies and interoceptive sensibility modulate the perception of non-evidence-based drug use: Findings from the COVID-19 outbreak. 2021 , 16, e0256806	0
516	How Brazil's President turned the country into a global epicenter of COVID-19. 2021 , 42, 439-451	11
515	The Evolution of Clinical Knowledge During COVID-19: Towards a Global Learning Health System. 2021 , 30, 176-184	2
514	QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia. 2021 , 37, 1184-1195	0
513	Viral load dynamics in intubated patients with COVID-19 admitted to the intensive care unit. 2021 , 64, 219-225	2
512	Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. 2021 ,	1
511	Remdesivir and Mortality in Patients with COVID-19. 2021 ,	5
510	Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. 2021 , 10,	6
509	Pharmacy practice in emergency response during the COVID-19 pandemic: Lessons from Australia. 2021 ,	4
508	Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19. 2021 ,	3
507	Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study. 2021 , 10,	0

506	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. 2021 , 93, 6737-6749	4
505	A model of the innate immune response to SARS-CoV-2 in the alveolar epithelium. 2021 , 8, 210090	1
504	Antirheumatic drugs and COVID-19: frustrations and hopes. 2021 , 134-139	
503	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. 2021 , 6, 317	17
502	Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. 2021 , 9, 851-862	54
501	[Rare superinfection in a COVID-19 patient-A chronology]. 2021 , 1	1
500	Reply. 2021 , 73, 1767-1768	
499	COVID-19: potential therapeutics for pediatric patients. 2021 , 73, 1520-1538	6
498	Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. 2021 , 28, e616-e619	3
497	Evidence-based public policy making for medicines across countries: findings and implications for the future. 2021 , 10, 1019-1052	7
496	TREATMENTS, RESOURCE UTILIZATION, AND OUTCOMES OF COVID-19 PATIENTS PRESENTING TO EMERGENCY DEPARTMENTS ACROSS PANDEMIC WAVES: AN OBSERVATIONAL STUDY BY THE CANADIAN COVID-19 EMERGENCY DEPARTMENT RAPID RESPONSE NETWORK (CCEDRRN).	2
495	Importance of nationally coordinated data collection and quality improvement networks. 1-3	
494	Clinical Research: From Case Reports to International Multicenter Clinical Trials. 2021 , 49, 1866-1882	3
493	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. 2021 , 136, 55-63	6
492	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. 2021 , 8, 713560	12
491	Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network. 2021 , 16, e0255644	3
490	Decreased Mortality Over Time During the First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study. 2021 , 22, 1565-1573.e4	2
489	Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study. 2021 , 174, 1395-1403	7

488	Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. 2021 , 27, 1124-1130	18
487	Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease. 2021 , 22, 2455-2474	0
486	Lectin from (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta. 2021 , 22,	3
485	The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic. 2021 , 114, 443-446	1
484	Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?. 2021 , 37, 1353-1364	5
483	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. 2021 , 6, 2305-2315	7
482	Current status of therapeutic alternatives for COVID-19: A narrative review.. 2021 , 29, 312-327	2
481	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). 2021 ,	16
480	Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. 2021 , 131, 105295	13
479	Clinical Outcomes and Independent Risk Factors for 90-Day Mortality in Critically Ill Patients with Respiratory Failure Infected with SARS-CoV-2: A Multicenter Study in Turkish Intensive Care Units. 2021 , 38, 296-303	3
478	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. 2021 , 2021, 5942366	2
477	Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. 2021 , 1-11	0
476	Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. 2021 , 193, 105127	6
475	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. 2021 , 23, 6364-6376	4
474	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. 2021 , 105, 584-595	3
473	Combination therapies for COVID-19: An overview of the clinical trials landscape. 2021 ,	4
472	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. 2021 , 17, e1009804	7
471	Adaptive Trials in Cardiology: Some Considerations and Examples. 2021 , 37, 1428-1437	

470	Endocytosis and Transcytosis of SARS-CoV-2 Across the Intestinal Epithelium and Other Tissue Barriers. 2021 , 12, 636966	6
469	Willingness to Treat with Therapies of Unknown Effectiveness in Severe COVID-19: A Survey of Intensivist Physicians. 2021 ,	1
468	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. 2021 , 9, 729559	7
467	Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. 2021 , 27, 1250-1261	19
466	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. 2021 , 6, 71	1
465	A hitchhiker's guide through the COVID-19 galaxy. 2021 , 232, 108849	0
464	Randomized controlled trials of traditional, complementary, and integrative medicine-based interventions for coronavirus disease 2019 (COVID-19): A bibliometric analysis and review of study designs. 2021 , 10, 100777	1
463	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial. 2021 , 174, 1261-1269	33
462	Risk factors for transfer from Respiratory Intermediate Care Unit to Intensive Care Unit in COVID-19. 2021 , 59, 602-607	3
461	Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients. 2021 ,	0
460	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. 2021 , 9, 957-968	26
459	Scientific evidence in the COVID-19 treatment: A comprehensive review. 2021 , 10, 217-228	1
458	Low dose hydroxychloroquine prophylaxis for COVID-19 in a prospective study.	
457	ERS International Congress 2020 Virtual: highlights from the Respiratory Intensive Care Assembly. 2021 , 7,	
456	Covid-19 and development of heart failure: mystery and truth. 2021 , 394, 2013-2021	9
455	COVID-19 en receptores de trasplante renal: ¿qu� hemos aprendido tras 18 meses de pandemia?. 2021 , 24, 219-231	
454	Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. 2021 , 135, 1076-1090	1
453	Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells. 2021 , 106, 103180	1

452	Management of SARS-CoV-2 pneumonia in intensive care unit: An observational retrospective study comparing two bundles. 2021 , 65, 200-204	0
451	Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors. 2021 , 223, 113622	4
450	Diabetes Mellitus and COVID-19: Review Article. 2021 , 15, 102268	2
449	Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. 2021 , 223, 113678	3
448	Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study. 2021 , 109, 108021	4
447	Novel treatments and trials in COVID-19. 2022 , 109-120	
446	Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. 2022 , 342-349	0
445	Lessons learned from COVID-19 therapies: Critical perspectives from the IDSA COVID-19 treatment guideline panel. 2021 ,	5
444	[Structure of hospital care for COVID-19 patients up to July 2020 in Germany]. 2021 , 116, 431-439	3
443	Clinical Profile and Outcomes of Confirmed COVID 19 at Manila Doctors Hospital. 2021 , 14, 1-10	
442	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. 2020 , 11, 588106	20
441	Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. 2020 , 7, 603961	16
440	COVID-19 Antiviral and Treatment Candidates: Current Status. 2021 , 21, e7	5
439	Severe COVID-19: A distinct entity. 2021 , 10, 84-92	0
438	High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. 2021 , 16, e0246396	2
437	Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. 2021 , 96-102	8
436	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219	11
435	Co-infection in patients with hypoxemic pneumonia due to COVID-19 in Reunion Island. 2021 , 100, e24524	5

434	Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study. 2021 , 9, E261-E270	9
433	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-Edged Swords. 2021 ,	0
432	Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract. 2021 , 9, e00698	7
431	Why do COVID death rates seem to be falling?. 2020 , 587, 190-192	28
430	COVID and 2020: An extraordinary year for science. 2020 , 588, 550-552	16
429	Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study. 2020 , 40,	11
428	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184	41
427	QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. 2020 ,	1
426	Bringing evidence from press release to the clinic in the era of COVID-19. 2021 , 76, 547-549	2
425	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.	7
424	Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.	4
423	Repurposed antiviral drugs for COVID-19 Interim WHO SOLIDARITY trial results.	85
422	A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19.	4
421	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.	2
420	Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.	2
419	Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. 2020 , 5,	20
418	Science in the Spotlight: A Crisis of Confidence?. 2021 , 6, 4-7	3
417	Pandemic trials: evidence-based medicine on steroids. 2020 , 56,	3

416	ACE2: the molecular doorway to SARS-CoV-2. 2020 , 10, 148	45
415	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. 2020 , 9, 1109	3
414	Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). 2020 , 15, e0242760	18
413	Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP). 2020 , 123, 6	10
412	Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. 2020 , 11, 590598	8
411	Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. 2020 , 8, 585832	32
410	Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. 2021 , 153, 219-226	1
409	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. 2021 , 2, 100063	2
408	Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study).	1
407	COVID-19 treatments sold online without prescription requirements in the United States. 2021 ,	1
406	Impact of Hydroxychloroquine Treatment of COVID-19 on Cardiac Conduction: The Beat Goes On. 2021 , 1, 458-464	
405	COVID-19 hospital prevalence as a risk factor for mortality: an observational study of a multistate cohort of 62 hospitals. 2021 ,	2
404	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. 2021 ,	2
403	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments.. 2022 , 30, 145-157	0
402	Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries. 2021 , 11, 20073	10
401	Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper. 2021 , 47, 199	2
400	How can we increase participation in pandemic research in Canada?. 2021 , 69, 293	1
399	COVID-19 and Cardiac Arrhythmias. 2021 , 41, 372-378	2

398	[Early initiation of corticosteroids might be harmful in patients hospitalized with COVID-19 pneumonia: A multicenter propensity score analysis.]. 2021 ,	0
397	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. 2021 , 73, 2151-2160	2
396	One step derivatization and dispersive liquid-liquid microextraction of hydroxychloroquine sulfate for its sensitive and accurate determination using GC-MS. 2021 , 107130	1
395	What went wrong: A reckoning of Canada's contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic.	1
394	Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts. 2021 ,	2
393	COVID-19 and the medicines regulation challenges in times of pandemic. 2021 , 26, 4693-4702	0
392	Hydroxychloroquine for COVID-19 infection: Do we have a final word after one year?. 2021 , 94, 4-5	0
391	Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital. 2021 , 95, 336-344	0
390	Formal and informal science advice in emergencies: COVID-19 in the UK.. 2021 , 11, 20210059	1
389	Extracorporeal Membrane Oxygenation for COVID 2019-Acute Respiratory Distress Syndrome: Comparison between First and Second Waves (Stage 2). 2021 , 10,	1
388	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. 2021 ,	0
387	Cancer and Covid-19: Collectively catastrophic. 2021 ,	3
386	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 , 9, 1419-1426	36
385	Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. 2021 , 13, 1215-1233	0
384	Mega randomized clinical trials: a definitive solution or a double-edged sword?. 2021 , 1	
383	Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop. 2021 , 39, 1455-1463	0
382	Repurposing old molecules for new indications: Defining pillars of success from lessons in the past. 2021 , 912, 174569	3
381	Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial. 2020 , 9, 1017	1

- 380 Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients. **2021**, 23, 271 0
- 379 Antimicrobial prescription in severe COVID-19 and CAP: a matched case-control study. **2021**, 1-8 0
- 378 Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19.. **2022**, 14, 95-104 0
- 377 COVID-19 Treatment at a Glance. **2020**, 21, 438-445 1
- 376 Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial. **2020**, 9, 1017 3
- 375 A Systematic Review and Network Meta-Analysis for COVID-19 Treatments.
- 374 Pandemic research for older people: doing it better next time. **2021**, 50, 276-278 3
- 373 Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations. **2020**, 11, 562038
- 372 Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?. **2021**, 16, 475-479 2
- 371 Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). **2021**, 1, 1 1
- 370 SARS-Cov-2 Viral Kinetics in Mild COVID-19 Patients Treated with Chloroquine Regimens or Standard of Care. **2021**, 3, 1-14
- 369 Complex Pathophysiological Mechanisms and the Propose of the Three-Dimensional Schedule For Future COVID-19 Treatment. **2021**, 12, 716940
- 368 SARS-CoV-2 infection in heart transplant recipients: a systematic literature review of clinical outcomes and immunosuppression strategies. **2021**, 1 0
- 367 Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. **2021**, 29, 1795-1805
- 366 Identification and Development of Therapeutics for COVID-19. **2021**, e0023321 5
- 365 Letter to the editor-a need to strengthen the adverse drug reaction reporting during COVID-19. **2021**, 33, 40
- 364 Governance frameworks for COVID-19 research ethics review and oversight in Latin America: an exploratory study. **2021**, 22, 147 0
- 363 Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event.

- 362 Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. **2021**, 3, e0566 0
- 361 Prevalence and Clinical Implications of COVID-19 Myocarditis.. **2022**, 14, 53-62 3
- 360 Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.
- 359 Self-medication practices to prevent or manage COVID-19: A systematic review. **2021**, 16, e0259317 10
- 358 Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens.
- 357 Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study. **2020**, 7, ofaa486 2
- 356 Gene Expression Meta-Analysis Reveals Interferon-induced Genes.
- 355 Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. 9, 1109 1
- 354 It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. **2021**, 17, 546-550
- 353 Medication use during COVID-19: Review of recent evidence. **2021**, 67, 171-179 1
- 352 . **2021**, 67, e69-e78
- 351 Drug Repurposing for the Treatment of Severe COVID-19 and the Impact on Disease Outcomes.
- 350 Treatment and therapeutic agents. **2022**, 121-176
- 349 Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. **2021**, 7, 6
- 348 Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report. **2021**, 15, 572 1
- 347 Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. **2021**, 1
- 346 Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment. **2021**, 73, 103
- 345 On Speeding Up and The Lunar Mare.. **2022**, 12, 10-12

344	Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. 2021 , 1	8
343	ESCMID COVID-19 Living guidelines: drug treatment and clinical management. 2021 ,	16
342	Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. 2021 , 2021, 4078713	1
341	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues.. 2021 , 9,	8
340	Pulmonary surfactant as a versatile biomaterial to fight COVID-19. 2021 , 342, 170-170	5
339	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. 6, 216	0
338	Covid-19: surging demand for some arthritis drugs. n2700	0
337	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. 2021 , 17, 1187-1198	0
336	Procalcitonin Increase Is Associated with the Development of Critical Care-Acquired Infections in COVID-19 ARDS. 2021 , 10,	4
335	Outcomes of Patients with Severe and Critical COVID-19 Treated with Dexamethasone: a Prospective Cohort Study. 2021 , 1-29	1
334	Antiviral Agents for Pediatric Ear, Nose, and Throat Infections. 2022 , 1021-1029	
333	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. 2021 , 12, 761887	6
332	COVID-19 and Cardiovascular System. Part 3. COVID-19 Current Treatment Approaches: Evidence-Based Review. 2021 , 10, 438-451	
331	Treatments for COVID-19: Lessons from 2020 and new therapeutic options.. 2021 , 62, 43-59	4
330	One-Year Multidisciplinary Follow-Up of Patients With COVID-19 Requiring Invasive Mechanical Ventilation.. 2021 ,	2
329	Directly and Simultaneously Expressing Absolute and Relative Treatment Effects in Medical Data Models and Applications. 2021 , 23,	2
328	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 ,	39
327	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. 2021 ,	2

326	Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. 2021 , 913, 174632	2
325	A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. 2021 , 10, 2256-2263	1
324	Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. 2021 , 319, 01035	
323	Repurposing Second life for drugs. 2022 , 69, 51-59	0
322	Acridavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses.. 2022 ,	4
321	Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19.. 2022 , 14, e20980	
320	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. 2022 , 5, e2142046	1
319	Overcoming barriers in the design and implementation of clinical trials for Acute Kidney Injury: a report from the 2020 Kidney Disease Clinical Trialists meeting.. 2022 ,	0
318	Lasciate ogni speranza voi che non sperimentate: il Recovery collaborative group e il Recovery fund. 2020 , 39, 551-552	1
317	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. 2020 , 17, 546-550	0
316	Management of Hospitalized Adult Patients with Coronavirus 2019 (COVID-19): A Therapeutic Guideline. 2021 , 9, 111-118	
315	SARS-CoV-2-host cell surface interactions and potential antiviral therapies.. 2022 , 12, 20200081	0
314	Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact.. 2022 , 17, e0262462	0
313	Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large Statewide Health System During the Pandemic in 2020.. 2022 , 38, 75-87	0
312	Low Selectivity Indices of Ivermectin and Macrocyclic Lactones on SARS-CoV-2 Replication In Vitro. 2022 , 2, 60-75	1
311	Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.. 2022 , 17, e0261843	0
310	Arrhythmias and Intraventricular Conduction Disturbances in Patients Hospitalized With Coronavirus Disease 2019.. 2022 , 162, 111-115	0
309	High-cited favorable studies for COVID-19 treatments ineffective in large trials.	

308	COVID MED IA An Early Pandemic Randomized Clinical Trial of Losartan for Hospitalized COVID-19 Patients.	
307	COVID-19: les thérapeutiques. 2022 , 1, 13-13	
306	COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.. 2022 , 14, e2022009	1
305	E-cigarette or Vaping product use Associated Lung Injury (EVALI) in the time of COVID-19: A clinical dilemma.. 2021 ,	0
304	Smarter adaptive platform clinical trials in neurology.. 2022 , 145, 409-410	0
303	A Balance Between Autophagy and Other Cell Death Modalities in Cancer.. 2022 , 2445, 3-24	
302	Pulmonary Aspects of COVID-19.. 2022 , 73, 81-93	2
301	An explanatory machine learning framework for studying pandemics: The case of COVID-19 emergency department readmissions.. 2022 , 113730	0
300	Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting.. 2022 ,	3
299	Analysis of Critical COVID-19 Cases Among Children in Korea.. 2022 , 37, e13	10
298	A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.. 2022 , 29, 337-349	2
297	Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.. 2022 , 22, 107	7
296	Viral infection as an NAD battlefield.. 2022 ,	1
295	An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.. 2021 , 55, e11631	1
294	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. 2022 ,	1
293	Management of Children Admitted to Hospitals across Bangladesh with Suspected or Confirmed COVID-19 and the Implications for the Future: A Nationwide Cross-Sectional Study.. 2022 , 11,	5
292	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients IA Systematic Review.	0
291	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.. 2021 , 12, 730127	0

290	The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.. 7, 24	1
289	A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry.. 2022 ,	1
288	Dexamethasone sensitizes to ferroptosis by glucocorticoid receptor-induced dipeptidase-1 expression and glutathione depletion.. 2022 , 8, eabl8920	2
287	Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure.. 2022 , 52, 151946	0
286	From hydroxychloroquine to ivermectin: how unproven "cures" can go viral.. 2022 ,	2
285	Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial.. 2022 , 17, e0261980	3
284	Natural Products and Nanotechnology Against Coronavirus Disease 2019.. 2022 , 10, 819969	1
283	Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. 2022 , 12, e051579	1
282	PHARMACOLOGIC TREATMENT AND MANAGEMENT OF COVID-19. 2022 ,	
281	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.. 2022 , 399, 665-676	43
280	Misinformation, believability, and vaccine acceptance over 40 countries: Takeaways from the initial phase of the COVID-19 infodemic.. 2022 , 17, e0263381	7
279	The Concept Of Repurposing In Covid-19 Infection. 2022 , 03,	
278	"H" is not for hydroxychloroquine-"H" is for heparin: lack of efficacy of hydroxychloroquine and the role of heparin in COVID-19-preliminary data of a prospective and interventional study from Brazil.. 2022 , 22, 120	0
277	COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments.. 2022 ,	0
276	Challenges and Innovations Brought about by the COVID-19 Pandemic Regarding Medical and Pharmacy Education Especially in Africa and Implications for the Future.. 2021 , 9,	6
275	Pharmacological treatment of COVID-19: an opinion paper. 2021 ,	10
274	Identification and Development of Therapeutics for COVID-19. 2021 ,	
273	Mucormycosis of the bones of the facial skull, nasal cavity and paranasal sinuses in patients with COVID19. 2021 , 23, 347-358	3

272	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN TRANSLATION). 2021 , 7, 28-70	
271	TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.. 2022 , 60, 496-509	0
270	COVID-19 Treatments Sold Online Without Prescription Requirements in the United States: Cross-sectional Study Evaluating Availability, Safety and Marketing of Medications (Preprint).	
269	Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia.. 2022 , 17, 9	0
268	COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients.. 2022 , 24, e13	2
267	. 2021 ,	
266	Health crisis: What opportunities for clinical drug research?. 2021 ,	0
265	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. 2022 , 11,	4
264	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. 2022 , e13763	1
263	Global challenges in preparedness and response to epidemic infectious diseases.. 2022 ,	1
262	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets.. 2022 , 23,	1
261	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.. 2022 , 14,	3
260	Reliability of citations of medRxiv preprints in articles published on COVID-19 in the world leading medical journals.	
259	Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron.	1
258	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.. 2022 , 7, 57	1
257	An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- α and hydroxychloroquine in hospitalized patients with COVID-19 [Final results from the DisCoVeRy trial.	0
256	NF- κ B Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?. 2022 , 11,	0
255	Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.. 2022 , 10,	2

254	Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine.. 2022 , 10, 804404	1
253	Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.. 2022 , 15,	0
252	Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.. 2022 , 10,	2
251	The Anti-Coronavirus Therapy (ACT) trials: design, baseline characteristics, and challenges.. 2022 ,	1
250	Reporting COVID-19 preprints: fast science in newspapers in the United States, the United Kingdom and Brazil.. 2022 , 27, 957-968	1
249	Hydroxychloroquine (HCQ) treatment for hospitalized patients with COVID- 19.. 2022 ,	
248	Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.. 2022 , 11,	3
247	How far are we from predicting multi-drug interactions during treatment for COVID-19 infection?. 2022 ,	
246	COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies.. 2022 , 14,	5
245	Ontology-Based Classification and Analysis of Adverse Events Associated With the Usage of Chloroquine and Hydroxychloroquine.. 2022 , 13, 812338	0
244	Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.. 2022 ,	0
243	Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.. 2022 , 23,	0
242	Emerging Therapies for COVID-19: the value of information from more clinical trials.	1
241	Accelerating Drug Discovery and Development. 2022 , 385-420	
240	Estimands and Complex Innovative Designs.. 2022 ,	0
239	SARS-CoV-2 infection and children: Insights from the 6th Workshop on Paediatric Virology (Review). 2022 , 4,	
238	Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2 including Delta and Omicron variants.. 2022 , 1-27	2
237	Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.. 2022 ,	1

236	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.	8
235	SARS-CoV-2 pathogenesis.. 2022 ,	30
234	Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.. 2022 ,	1
233	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters.. 2022 , e0370521	1
232	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.. 2022 , 12, e048502	3
231	Current challenges in different approaches to control COVID-19: a comprehensive review.. 2022 , 46, 47	0
230	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. 2022 ,	1
229	On the role of data, statistics and decisions in a pandemic.. 2022 , 1-34	1
228	Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial.. 2022 , 23, 273	
227	Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN).. 2022 , 1	2
226	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. 2022 , 179, 106201	3
225	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. 2022 ,	0
224	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. 2022 , 11, 100243	0
223	Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020. 2021 , 93, 1306-1315	1
222	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines.. 2021 , 11, 763687	1
221	Interim-analysis of the COSA (COVID-19 patients treated with the Seraph [®] 100 Microbind [®] Affinity filter) registry. 2021 ,	3
220	Immune dysfunction in COVID-19 and judicious use of anti-rheumatic drugs for the treatment of hyperinflammation. 2021 ,	1
219	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. 2021 , 39-68	

218 Real-world response of COVID-19 patients in Mexico.

217 Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.. **2021**, 11, 1

216 Clinical trials during the COVID-19 pandemic: research design and lessons. **2021**, 214-231

215 The quandary over Antiviral Therapy for a COVID-19 Patient with Glucose-6-Phosphate Dehydrogenase Deficiency, Hypertension, and Resolved Hepatitis B Infection: A Case Report. **2021**, 9, 221-224

214 Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019.. **2022**, 9, ofab581 3

213 Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19.. **2021**, 12, 763292 5

212 A Patient-Specific Re-Engineered Cardiomyocyte Model Confirms the Circumstance-Dependent Arrhythmia Risk Associated with the African-Specific Common SCN5A Polymorphism (p.S1103Y): Implications for the Increased Sudden Deaths Observed in Black Individuals During the COVID-19 Pandemic.. **2021**, 0

211 ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. **2021**, 3

210 The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations.. **2021**, 3

209 Finding of the factors affecting the severity of COVID-19 based on mathematical models.. **2021**, 11, 24224 1

208 Leveraging Drug-Target Interaction Data for the Translation of Computational Models into Clinically Actionable Interventions. **2021**,

207 Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.. **2021**, 22, 3

206 COVID-19 and the liver: A brief and core review.. **2021**, 13, 2013-2023 2

205 Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.. **2021**, 14, 2

204 Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients. **2021**, 2, 3

203 Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report. **2021**, 9, 225-229

202 Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics.. **2022**, 8, e1268 3

201 Universities' Scientific and Technological Transformation in China: Its Efficiency and Influencing Factors in the Yangtze River Economic Belt.. **2021**, 16, e0261343 0

- 200 Overview of clinical trials of drugs for the treatment of patients with new coronavirus infection (COVID-19). **2021**, 21, 177-190
- 199 Drug safety of frequently used drugs and substances for self-medication in COVID-19.. **2022**, 13, 20420986221094141
- 198 COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.. **2022**, 4
- 197 Corticosteroids in COVID-19: A double-edged sword - a retrospective study.. **2022**, 46, 229-231
- 196 Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19.
- 195 Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease.. **2022**, 1
- 194 Presentation_1.pptx. **2020**,
- 193 Table_1.xlsx. **2020**,
- 192 datasheet1.pdf. **2020**,
- 191 image1.jpeg. **2020**,
- 190 table1.xlsx. **2020**,
- 189 table2.xlsx. **2020**,
- 188 datasheet1.pdf. **2020**,
- 187 Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).. **2022**, 134, 399
- 186 Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.. **2022**, 109954 0
- 185 Medication use during COVID-19. **2021**, 67, 171-179 2
- 184 Mdicaments utilisés durant la COVID-19. **2021**, 67, e69-e78
- 183 Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.. **2022**, 33, 487-536

182	Neutrophils inhibit CD8+ T cells immune response by arginase-1 signaling in patients with sepsis. 2022 , 13,	1
181	Validation of Machine Learning Models to Predict Adverse Outcomes in Patients with COVID-19: A Prospective Pilot Study.. 2022 , 63, 422-429	0
180	Epidemiology and Clinical Characteristics of People with Confirmed SARS-CoV-2 Infection during the Early COVID-19 Pandemic in Saudi Arabia. 2022 , 9, 32	
179	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. 2022 , 11, 516	1
178	Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels.. 2022 , 23,	0
177	Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.. 2022 ,	0
176	Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.. 2022 , 109022	2
175	Self-Medication during the Era of COVID-19; Potential Implications for Drug Policy Makers and Pharmacovigilance. 2022 , 17,	
174	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality).. 2022 ,	0
173	Clinical Characteristics, Risk Factors for Severity and Pharmacotherapy in Hospitalized COVID-19 Patients in the United Arab Emirates.. 2022 , 11,	0
172	Self-Reported Medication Use among Pregnant and Postpartum Women during the Third Wave of the COVID-19 Pandemic: A European Multinational Cross-Sectional Study.. 2022 , 19,	1
171	Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. 2022 ,	0
170	Early Corticosteroid Therapy May Increase Ventilator-Associated Lower Respiratory Tract Infection in Critically Ill Patients with COVID-19: A Multicenter Retrospective Cohort Study. 2022 , 10, 984	1
169	Assessing mortality differences across acute respiratory failure management strategies in Covid-19.. 2022 , 70, 154045	0
168	Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.. 2022 , 1-9	0
167	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. 2022 , 20,	
166	Being a Public Health Statistician During a Global Pandemic. 2022 , 37,	0
165	Effect of ArtemiC in patients with COVID-19: A Phase II prospective study.. 2022 ,	2

- 164 Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. **2022**, 15, 634 1
- 163 Equipose, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials. medethics-2022-108182 1
- 162 Efficacy of COVID-19 treatments among geriatric patients: a systematic review. **2022**, 9, 204993612210956 0
- 161 Journey of Chloroquine/ Hydroxychloroquine in the management of COVID-19. **2022**, 110-116
- 160 Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey. **2022**, 2, 649-659
- 159 Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. 1
- 158 Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis.
- 157 Influence of statin treatment in a cohort of patients admitted for COVID-19. **2022**, 1
- 156 Favipiravir in Early Symptomatic COVID-19, A Randomised Placebo-Controlled Trial.
- 155 Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Volume 18, 603-617 0
- 154 Liver Injuries Associated with Coronavirus Disease 2019: View on the Problem. **2022**, 1-2, 67-74
- 153 Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. **2022**, 7, 3
- 152 Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. **2022**, 1
- 151 Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. **2022**, 10, 919 2
- 150 Large scale clinical trials: lessons from the COVID-19 pandemic. **2022**, 9, e001226 1
- 149 Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalized with COVID-19 during the First Five Waves of the Pandemic in Pakistan; Findings and Implications. **2022**, 11, 789 5
- 148 Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform. 0
- 147 Lessons from SARS-CoV-2 and its variants (Review). **2022**, 26, 0

- 146 Clinical and Genetic Characteristics of Coronaviruses with Particular Emphasis on SARS-CoV-2 Virus. **2022**, 71, 141-159
- 145 Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. **2022**, 15, 739 2
- 144 Coronavirus disease 2019 and the cardiologist. **2022**, 37, 335-342
- 143 Currently available drugs for the treatment of Coronavirus-2. **2022**, 77-95
- 142 Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro. **2022**, 14, 1404 1
- 141 A Review on SARS-CoV-2 Genome in the Aquatic Environment of Africa: Prevalence, Persistence and the Future Prospects. **2022**, 14, 2020
- 140 Dexamethasone: Therapeutic Applications, Targets and Translation.
- 139 Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. **2022**, 10, 1284 1
- 138 Therapeutic Interventions Implemented During the First Year of the COVID-19 Pandemic: A Systematic Review of Evidence. **2022**, 7, 287-302
- 137 Digital HealthEnabled Clinical Trials in Stroke: Ready for Prime Time?. 0
- 136 Leveraging Real-World Data in COVID-19 Response. 1-33
- 135 The cross-over of statistical thinking and practices: A pandemic catalyst. **2022**, 21, 778-789
- 134 Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors.
- 133 Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. **2022**, 26, 2
- 132 Exploring Knowledge of Antibiotic Use, Resistance, and Stewardship Programs among Pharmacy Technicians Serving in Ambulatory Care Settings in Pakistan and the Implications. **2022**, 11, 921 1
- 131 Optimizing the Design and Analysis of Future AKI Trials. ASN.2021121605 0
- 130 Pharmacy students' knowledge and confidence of COVID-19 following an interactive didactic class.
- 129 Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. **2022**, 11, 269-297 0

- 128 Rheumatology research in the post-COVID era—challenges and solutions. 0
- 127 Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties. **2022**, 15, 831 0
- 126 Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial. **2022**, 100901 1
- 125 COVIDMED [An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients. **2022**, 100968 1
- 124 How the Malian press treated hydroxychloroquine at the beginning of the COVID-19 pandemic.
- 123 Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. **2022**, 400, 359-368 2
- 122 The effect of coronavirus infection on QT and QTc intervals of hospitalized patients in Qazvin, Iran.
- 121 Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation.
- 120 Comparison between the first and second COVID-19 waves in Internal Medicine wards in Milan, Italy: a retrospective observational study. 2
- 119 Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study. **2022**, 22, 0
- 118 Absolute binding free energies of mucroporin and its analog mucroporin-M1 with the heptad repeat 1 domain and RNA-dependent RNA polymerase of SARS-CoV-2. 1-12
- 117 A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics. 1
- 116 Treatments for the Infection by SARS-CoV-2.
- 115 COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. **2022**, 28, 2211-2233
- 114 The Impact of Landscape Changes on Data and Safety Monitoring Board Oversight of Clinical Trials. **2022**, 1, 1
- 113 PRACTICE OF SELF-MEDICATION AND QUALITY OF LIFE ASSESSMENT AMONG HEALTHCARE WORKERS OF A TERTIARY HOSPITAL IN ASSAM DURING COVID-19 PANDEMIC. 184-189
- 112 A review of clinical efficacy data supporting emergency use authorization for COVID -19 therapeutics and lessons for future pandemics. 1
- 111 Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. 13, 0

110	A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate using ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry and liquid chromatography-solid-phase extraction-nuclear magnetic resonance. 2022 , 36,	
109	Immune-related adverse events of biological immunotherapies used in COVID-19. 13,	0
108	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.	1
107	Acceptability and Willingness of UAE Residents to Use OTC Vending Machines to Deliver Self-Testing Kits for COVID-19 and the Implications. Volume 15, 1759-1770	0
106	Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.	3
105	Reliability of citations of medRxiv preprints in articles published on COVID-19 in the world leading medical journals. 2022 , 17, e0264661	0
104	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. 2022 , 111, 109161	2
103	The scenario of self-medication practices during the covid-19 pandemic; a systematic review. 2022 , 82, 104482	2
102	Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control. 55,	0
101	Vitamin D: a potentially important secosteroid for coping with COVID-19. 2022 , 94,	0
100	Consensus of the Liaison-Psychiatry Committee of the Colombian Psychiatric Association on the diagnosis and treatment of delirium in the context of the COVID-19 pandemic. 2022 , 51, 245-255	0
99	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. 2022 , 92, 430-436	0
98	Outpatient Management of COVID-19: A Primer for the Dermatologist.	0
97	Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation.	0
96	Chloroquine disrupts zinc storage granules in primary Malpighian tubule cells of <i>Drosophila melanogaster</i> .	0
95	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. 2022 , 12, 1456	0
94	Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	0
93	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. 2022 ,	0

92	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. 2022 , 20,	0
91	Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.	0
90	Coronavirus Disease 2019 (COVID-19) Pandemic across Africa: Current Status of Vaccinations and Implications for the Future. 2022 , 10, 1553	5
89	Untargeted saliva metabolomics by liquid chromatographyMass spectrometry reveals markers of COVID-19 severity. 2022 , 17, e0274967	1
88	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 20212022. 2022 , 7, 163-169	0
87	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. 13,	0
86	Managing two waves of the COVID-19 pandemic in northern emergency departments in Paris: COVIDORG II. 2022 , 34, 70-81	0
85	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. 1-21	1
84	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. 2022 , 17, e0273526	0
83	Evaluation of S/F94 as a proxy for COVID-19 severity.	0
82	Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemic. 2022 , 17, e0267815	0
81	Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. 2022 ,	0
80	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. 2022 , 217, 368-378	1
79	COVID-19-associated AKI. Publish Ahead of Print,	3
78	Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. 2022 , 1, e000309	1
77	Medications for early treatment of COVID -19 in Australia.	0
76	Intrapulmonary shunting is a key contributor to hypoxia in COVID-19: An update on the pathophysiology. 2022 , 17, e0273402	0
75	Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19. 2022 , 23,	0

74	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. 2022 , 44,	0
73	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. 13,	1
72	Pharmacological therapies and drug development targeting SARS-CoV-2 infection. 2022 ,	0
71	Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later. 2022 , 20, 762-767	0
70	Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. 2022 , 25, 105316	2
69	Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. 2022 , 54, 101703	2
68	V. Current Treatment Approach for COVID-19. 2021 , 110, 2374-2382	0
67	Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. 2022 ,	0
66	Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021.	0
65	Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. 2022 , 20,	1
64	Tratamiento prehospitalario en COVID-19 atendidos en un hospital de referencia de la Ciudad de México. 2022 , 81, 80-85	0
63	COVID-19 Outbreak in Daegu City, Korea and Response to COVID-19: How Have We Dealt and What Are the Lessons?. 2022 , 37,	2
62	How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea. 2022 , 37,	0
61	Arzneimittelnutzung unter Pandemiebedingungen. 2022 , 171-187	0
60	Zinc sulfide-based hybrid exosome-coated nanoplatfrom for targeted treatment of glioblastoma in an orthotopic mouse glioblastoma model. 2023 , 17, 100327	0
59	The Impact of Prior Antithrombotic use on Thromboembolic Events in Patients with Cardiovascular Disease and Severe COVID-19 Infection. 2022 , 28, 107602962211414	0
58	A 90-year-old Woman with COVID-19 Infection While Receiving Low-dose Prednisolone and Cyclosporine for the Treatment of Nephrotic Syndrome. 2021 , 110, 2601-2606	0
57	Honey and Nigella sativa against COVID -19 in Pakistan (HNS-COVID-PK): A multicenter placebo-controlled randomized clinical trial.	0

- 56 Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective. ○
- 55 Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. **2022**, 14, 2551 ○
- 54 COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis. **2022**, 11, 6865 ○
- 53 Hydroxychloroquine is metabolized by CYP2D6, CYP3A4, and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A in vitro. DMD-AR-2022-001018 ○
- 52 Fomepizole should not be used more liberally in paracetamol overdose. ○
- 51 A New Role of amantadines in COVID-19 in patients with Parkinson's disease: results of own comparative study. **2022**, 14, 40-48 ○
- 50 ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. **2022**, 23, ○
- 49 Outcomes in Patients with Acute Hypoxemic Respiratory Failure Secondary to COVID-19 Treated with Noninvasive Respiratory Support versus Invasive Mechanical Ventilation. ○
- 48 Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ○
- 47 Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. 6, 216 ○
- 46 Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. **2022**, 20, ○
- 45 Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials. ○
- 44 Anthracyclines inhibit SARS-CoV-2 infection. ○
- 43 The evidence base for emergency use authorizations for COVID-19 treatments: A rapid review. **2023**, 6, ○
- 42 Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers. ○
- 41 Progression of ECG in hydroxychloroquine overdose. **2023**, 77, 68-71 ○
- 40 COVID-19: Cardiology Perspective. **2023**, 361-388 ○
- 39 COVID-19 in Pediatrics. **2023**, 255-289 ○

38	COVID-19: Inpatient Management. 2023 , 182-232	0
37	The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic.	1
36	Evaluation of anakinra in the management of patients with COVID-19 infection: A randomized clinical trial. 14,	0
35	Investigation on the Essential Oils of the Achillea Species: From Chemical Analysis to the In Silico Uptake against SARS-CoV-2 Main Protease. 2023 , 13, 378	0
34	COVID-19 in Older Adults. 2023 , 1-19	0
33	Antimalarial drugs. 2023 , 363-396	0
32	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59,	0
31	Hydroxychloroquine: Time for Reappraisal of Its Effect in COVID-19 Patients. 2023 , 431-439	0
30	Evaluation of patients treated by telemedicine in the beginning of the COVID-19 pandemic in Sß Paulo, Brazil: A non-randomized clinical trial preliminary study. 2023 , e15337	0
29	SARS-CoV-2-Induced Myocarditis: A State-of-the-Art Review. 2023 , 15, 916	0
28	An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics. 2023 , 76, 13-22	0
27	The development of COVID-19 treatment. 14,	2
26	Assessing the Clinical Characteristics and Management of COVID-19 among Pediatric Patients in Ghana: Findings and Implications. 2023 , 12, 283	1
25	Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2+/- atrial cardiomyocytes.	0
24	Is it reasonable to label a trial as pragmatic whose investigators do not? The UK RECOVERY COVID-19 trial case. 174077452311528	0
23	COVID -19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats. 2023 , 11,	0
22	Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19. 2023 , 15, 159	0
21	Current and Emerging Therapies for COVID-19 in Lung Transplantation.	0

- 20 Comparison of patients admitted to an inner-city intensive care unit across 3 COVID-19 waves. **2023**, 102, e33069 ○
- 19 Knowledge, Attitude and Practices of Self-Medication Including Antibiotics among Health Care Professionals during the COVID-19 Pandemic in Pakistan: Findings and Implications. **2023**, 12, 481 ○
- 18 Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. **2023**, 42, 373-383 1
- 17 Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. **2023**, 59, 541 ○
- 16 A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations. 14, ○
- 15 Effectiveness of Fortified Garlic Extract Oral Capsules as Adjuvant Therapy in Hospitalized Patients with Coronavirus Disease 2019: A Triple-Blind Randomized Controlled Clinical Trial. **2023**, 98, 100699 ○
- 14 Towards achieving transnational research partnership equity: lessons from implementing adaptive platform trials in low- and middle-income countries. 8, 120 ○
- 13 Antibiotic Overprescribing among Neonates and Children Hospitalized with COVID-19 in Pakistan and the Implications. **2023**, 12, 646 ○
- 12 Non-US regulatory. **2023**, 553-559 ○
- 11 Long COVID in autoimmune rheumatic diseases. ○
- 10 Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients. ○
- 9 The HAVEN studyHydroxychloroquine in ANCA vasculitis evaluation: multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. **2023**, 24, ○
- 8 Therapeutics for COVID-19. **2024**, 282-307 ○
- 7 Exploring the Link Between Malaria and COVID-19. **2023**, 311-338 ○
- 6 The positive impact of COVID-19 on critical care: from unprecedented challenges to transformative changes, from the perspective of young intensivists. **2023**, 13, ○
- 5 Trends in management and outcomes of COVID patients admitted to a Swiss tertiary care hospital. **2023**, 13, ○
- 4 Acute kidney injury in COVID-19 patients receiving remdesivir: a systematic review and meta-analysis of randomized clinical trials. **2023**, 100200 ○
- 3 Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ○

2	Resultados en la práctica asistencial y coste marginal del tratamiento con tocilizumab en pacientes COVID-19. 2023 , 47, 10-15	o
1	[Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients. 2023 , 47, T10-T15	o